Next Article in Journal
To What Extent Should We Rely on Antibiotics to Reduce High Gonococcal Prevalence? Historical Insights from Mass-Meningococcal Campaigns
Next Article in Special Issue
Papillomaviruses Go Retro
Previous Article in Journal
Identification of a Neisseria gonorrhoeae Histone Deacetylase: Epigenetic Impact on Host Gene Expression
Previous Article in Special Issue
Surfactant Protein A Impairs Genital HPV16 Pseudovirus Infection by Innate Immune Cell Activation in A Murine Model
Review

HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy?

1
Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia
2
International Centre for Genetic Engineering and Biotechnology, AREA Science Park, Padriciano 99, I-34149 Trieste, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pathogens 2020, 9(2), 133; https://doi.org/10.3390/pathogens9020133
Received: 20 December 2019 / Revised: 10 February 2020 / Accepted: 11 February 2020 / Published: 18 February 2020
Human papillomavirus (HPV) E6 and E7 oncoproteins are critical for development and maintenance of the malignant phenotype in HPV-induced cancers. These two viral oncoproteins interfere with a plethora of cellular pathways, including the regulation of cell cycle and the control of apoptosis, which are critical in maintaining normal cellular functions. E6 and E7 bind directly with certain components of the Ubiquitin Proteasome System (UPS), enabling them to manipulate a number of important cellular pathways. These activities are the means by which HPV establishes an environment supporting the normal viral life cycle, however in some instances they can also lead to the development of malignancy. In this review, we have discussed how E6 and E7 oncoproteins from alpha and beta HPV types interact with the components of the UPS, and how this interplay contributes to the development of cancer. View Full-Text
Keywords: E6; E7; HPV; cervical cancer; proteasome; UPS; ubiquitin ligases; ubiquitin E6; E7; HPV; cervical cancer; proteasome; UPS; ubiquitin ligases; ubiquitin
Show Figures

Figure 1

MDPI and ACS Style

Đukić, A.; Lulić, L.; Thomas, M.; Skelin, J.; Bennett Saidu, N.E.; Grce, M.; Banks, L.; Tomaić, V. HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy? Pathogens 2020, 9, 133. https://doi.org/10.3390/pathogens9020133

AMA Style

Đukić A, Lulić L, Thomas M, Skelin J, Bennett Saidu NE, Grce M, Banks L, Tomaić V. HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy? Pathogens. 2020; 9(2):133. https://doi.org/10.3390/pathogens9020133

Chicago/Turabian Style

Đukić, Anamaria, Lucija Lulić, Miranda Thomas, Josipa Skelin, Nathaniel E. Bennett Saidu, Magdalena Grce, Lawrence Banks, and Vjekoslav Tomaić. 2020. "HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy?" Pathogens 9, no. 2: 133. https://doi.org/10.3390/pathogens9020133

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop